Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03113487 · ClinicalTrials.gov registry record · Phase 2
P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
A Phase 2 study of Recurrent Platinum-Resistant Ovarian Carcinoma and Recurrent Platinum-Resistant Fallopian Tube Carcinoma, sponsored by City of Hope Medical Center.
- Active
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT03113487 is a Phase 2 study of Recurrent Platinum-Resistant Ovarian Carcinoma and Recurrent Platinum-Resistant Fallopian Tube Carcinoma that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 29 participants, below the 37-participant average among 5 other Recurrent Platinum-Resistant Ovarian Carcinoma trials with a reported enrollment target (22% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03113487, a Phase 2 study of Recurrent Platinum-Resistant Ovarian Carcinoma and Recurrent Platinum-Resistant Fallopian Tube Carcinoma, is active but no longer recruiting, sponsored by City of Hope Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well modified vaccinia virus ankara vaccine expressing p53 (p53MVA) and pembrolizumab work in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back (recurrent). Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving p53MVA and pembrolizumab together may work better in treating patients with ovarian, primary peritoneal, or fallopian tube cancer.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL Modified Vaccinia Virus Ankara Vaccine Expressing p53
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2018-02-01 |
| Est. Completion | 2026-05-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03113487
The ClinicalTrials.gov registry entry for NCT03113487 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 37-participant average among 5 other Recurrent Platinum-Resistant Ovarian Carcinoma trials with a reported enrollment target (22% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Recurrent Platinum-Resistant Ovarian Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03113487 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03113487 about?
NCT03113487 is a clinical study titled "P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer". This phase II trial studies how well modified vaccinia virus ankara vaccine expressing p53 (p53MVA) and pembrolizumab work in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back (recurrent). Vaccines made from a gene-modified virus may help the body build ...
What is the current status of trial NCT03113487?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2018-02-01. Estimated completion is 2026-05-04.
What conditions does trial NCT03113487 study?
This clinical trial studies the following conditions: Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma.
What interventions are being tested in trial NCT03113487?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Modified Vaccinia Virus Ankara Vaccine Expressing p53 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03113487?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03113487 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Platinum-Resistant Ovarian Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
RECRUITING · Phase 1
-
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
RECRUITING · Phase 1
-
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
RECRUITING · Phase 1
-
DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
RECRUITING · Phase 1
-
MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Recurrent Platinum-Resistant Ovarian Carcinoma
All registered trials for this condition
Recurrent Platinum-Resistant Fallopian Tube Carcinoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.